Intravenous colistin use for infections due to MDR Gram-negative bacilli in critically ill paediatric patients: A systematic review and meta-analysis
Date
2019Language
en
Keyword
Abstract
Background: Data are limited regarding the clinical effectiveness and safety of intravenous colistin for treatment of infections due to MDR Gram-negative bacilli (GNB) in paediatric ICUs (PICUs). Methods: Systematic review of intravenous colistin use in critically ill paediatric patients with MDR-GNB infection in PubMed, Scopus and EMBASE (up to 31 January 2018). Results: Out of 1181 citations, 7 studies were included on the use of intravenous colistin for 405 patients in PICUs. The majority of patients were diagnosed with lower respiratory tract infections, Acinetobacter baumannii being the predominant pathogen. Colistin dosages ranged between 2.6 and 18 mg/kg/day, with only one case reporting a loading dose. Emergence of colistin resistance during treatment was reported in two cases. Nephrotoxicity and neurotoxicity were reported in 6.1% and 0.5%, respectively, but concomitant medications and severe underlying illness limited our ability to definitively associate use of colistin with nephrotoxicity. Crude mortality was 29.5% (95% CI=21.7%-38.1%), whereas infection-related mortality was 16.6% (95% CI=12.2%-21.5%). Conclusions: While the reported incidence of adverse events related to colistin was low, reported mortality rates for infections due to MDR-GNB in PICUs were notable. In addition to severity of disease and comorbidities, inadequate daily dosage and the absence of a loading dose may have contributed to mortality. As the use of colistin for treatment of MDR-GNB infections increases, it is imperative to understand whether optimal dosing of colistin in paediatric patients differs across different age groups. Thus, future studies to establish the pharmacokinetic properties of colistin in different paediatric settings are warranted. © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Risk factors for the first episode of Acinetobacter baumannii resistant to colistin infection and outcome in critically ill patients
Mantzarlis K., Makris D., Zakynthinos E. (2020)Introduction. To identify risk factors for the first episode of Acinetobacter baumannii resistant to colistin (ABCR) infection in critically ill patients. Aim. Prospective observational study. Methodology. ICU patients who ... -
ICU-Associated Gram-Negative Bloodstream Infection: Risk Factors Affecting the Outcome Following the Emergence of Colistin-Resistant Isolates in a Regional Greek Hospital
Karvouniaris M., Poulakou G., Tsiakos K., Chatzimichail M., Papamichalis P., Katsiaflaka A., Oikonomou K., Katsioulis A., Palli E., Komnos A. (2022)Intensive care unit patients may present infections by difficult-to-treat-resistant Gram-negative microorganisms. Colistin resurfaced as a last resort antibiotic for the treatment of multidrug-resistant Gram-negative ... -
Confronting multidrug-resistant Acinetobacter baumannii: a review
Neonakis, I. K.; Spandidos, D. A.; Petinaki, E. (2011)Multidrug-resistant Acinetobacter baumannii (MDR-AB) infections are difficult to treat owing to the extremely limited armamentarium. The present review reports all available treatment options against MDR-AB, including ...